本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a significant milestone in AI-powered radiology research Key studies demonstrate AI's capability to replace one radiologist in double reading, detect subclinical breast cancer years in advance, and maintain robust performance despite image quality challenges SEOUL, South Korea, Feb. 27, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a landmark achievement at the European Congress of Radiology (ECR) 2025, taking place in Vienna, Austria, from February 26 to March 2. With 15 research abstracts accepted and 13 designated as oral presentations, this year's participation marks Lunit's largest and most influential presence at ECR to date. The high acceptance rate underscores Lunit's growing leadership in AI-driven radiology, with its research recognized as highly relevant to the future of cancer screening and detection. Among the featured studies, two highlight groundbreaking findings that further solidify Lunit INSIGHT MMG as a clinically proven tool in mammography interpretation and workflow optimization. Replacing One Radiologist with AI for Independent Double Reading in Mammographic Screening Presented by Marie Burns Bergan from BreastScreen Norway, this study evaluates the impact of replacing one radiologist with Lunit INSIGHT MMG in a large-scale double-reading mammography screening program. The research analyzed over 1 million mammography screenings, testing various AI thresholds to assess AI's role in maintaining detection accuracy while reducing radiologists' workload. Key findings include: AI successfully detected up to 79.9% of screen-detected cancers at a 10% positivity threshold. At a 5% threshold, AI maintained 75.5% cancer detection while also identifying 5.7% of interval cancers, which are often missed by traditional screening. AI integration reduced radiologists' reading workload by 50%, optimizing resources without significantly compromising detection accuracy. This study highlights Lunit INSIGHT MMG's ability to serve as a reliable second reader, supporting AI's role in improving efficiency and alleviating radiologist shortages in high-volume screening programs. Using Artificial Intelligence to Detect Subclinical Breast Cancer Led by Jonas Gjesvik from BreastScreen Norway, this study investigates whether Lunit INSIGHT MMG can identify subtle cancer risk indicators years before a formal diagnosis. The analysis involved 116,000 women who participated in a long-term mammography screening program, assessing AI's ability to assign risk scores and track disease progression. Key findings include: AI assigned higher risk scores to breasts that later developed cancer, even up to six years before diagnosis. AI scores for screen-detected breast cancers increased significantly from 19.2 to 82.7 across consecutive screenings, indicating early disease detection. For interval cancers, AI identified elevated risk earlier than traditional methods, paving the way for more personalized screening strategies. The study underscores AI's potential to enhance breast cancer risk prediction, shifting screening protocols toward a personalized, risk-based model. This research aligns with ongoing work leveraging Volpara's breast density analysis, further strengthening the Lunit-Volpara ecosystem in AI-driven breast cancer risk assessment. In addition to these highlighted studies, Lunit will present a total of 15 research abstracts, further demonstrating AI's role in enhancing diagnostic accuracy, optimizing workflow, and supporting radiologists worldwide. "This year's ECR is a landmark moment for Lunit, with our highest-ever number of oral presentations, underscoring our leadership in AI-powered radiology research," said Brandon Suh, CEO of Lunit. "From replacing a radiologist in double-reading settings to predicting breast cancer years in advance, these findings reinforce AI's potential to transform breast cancer detection, optimize radiology workflows, and ultimately improve patient outcomes." Join Lunit at booth AI-19 in the EXPO X1 hall to explore the latest advancements in AI-powered cancer detection and discuss potential collaborations in the evolving field of AI-driven radiology. Presentations featuring Lunit INSIGHT at ECR 2025 Lunit INSIGHT MMG, Oral Presentation, RPS-2202 "Associations of automatically measured breast density with breast cancer risk and duration of the pre-clinical detectable phase in a Dutch screening cohort" | March 2 at 08:00-09:00 CET, Research Stage 1 Lunit INSIGHT MMG, Oral Presentation, RPS-2202 "Impact of Breast Density Metrics on Personalized Breast Cancer Screening Protocols" | March 2 at 08:00-09:00 CET, Research Stage 1 Lunit INSIGHT MMG, Oral Presentation, RPS-2202 "Changes in Mammographic Density for Breasts Developing and not Developing Breast Cancer" | March 2 at 08:00-09:00 CET, Research Stage 1 Lunit INSIGHT MMT, EPOS, C-16155 "Breast volume for women with screen-detected and interval cancer in BreastScreen Norway" Lunit INSIGHT MMG, Oral Presentation, RPS-1002 "Replacing one radiologist with AI for independent double reading in mammographic screening" | Feb 27 at 14:00-15:30 CET, Research Stage 4 Lunit INSIGHT MMG, Oral Presentation, RPS-1002 "The application of artificial intelligence to enhance the identification of previously missed non-palpable breast carcinomas" | Feb 27 at 14:00-15:30 CET, Research Stage 4 Lunit INSIGHT MMG, Poster Presentation, C-18295 "Radiologist's interpretation scores on cancer cases among the screening examinations with the highest AI malignancy scores in BreastScreen Norway" Lunit INSIGHT MMG, Oral Presentation, RPS-2202 "Using Artificial Intelligence to Detect Subclinical Breast Cancer" | March 2 at 08:00-09:00 CET, Research Stage 1 Lunit INSIGHT MMG, Oral Presentation, RPS-1002 "Mammographic features of false positive AI markings on screening mammograms from BreastScreen Norway" | Feb 27 at 14:00-15:30 CET, Research Stage 4 Lunit INSIGHT MMG, Oral Presentation, RPS-705 "Artificial intelligence mammography interpretation systems are affected more by mammographic image quality issues than radiologists are" | Feb 27 at 08:00-09:30 CET, Research Stage 3 Lunit INSIGHT MMG, Oral Presentation, RPS-705 "Repurposed AI-Based Mammography Interpretation in Diverse Clinical Scenarios" | Feb 27 at 08:00-09:30 CET, Research Stage 3 Lunit INSIGHT MMG, Oral Presentation, RPS-1902 "Artificial intelligence as an initial reader for double reading in breast cancer screening: A prospective initial study of 32,822 mammograms of the Egyptian population" | March 1 at 12:30-13:30 CET, Research Stage 1 Lunit INSIGHT MMG, Oral Presentation, S10 - Students session 1 "Menopausal status and breast density" | Feb 27 at 14:00-15:30 CET, Room M1 Lunit INSIGHT DBT, Oral Poster Presentation, C-12965 "Acceptability of tomosynthesis in breast cancer screening to participants and screening professionals in the Netherlands" | Feb 26 at 15:30 CET, Poster Presentation Stage B Lunit INSIGHT MMG, Oral Presentation, RPS-1705 "Exploring how AI influences human gaze behaviour during mammography reading" | March 1 at 08:00-09:00 CET, Research Stage 4 About Lunit Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 hospitals and medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city. This onsite inspection covered the facilities' quality processes and the entire production system. It concluded without issues, demonstrating the company's robust expertise in meeting global regulatory requirements. To date, WuXi Biologics has successfully passed 42 regulatory inspections and has received 97 license approvals from drug administration agencies across multiple countries and regions, including the U.S., Europe, China, Singapore, Japan and Canada. The company's track record of successful inspections underscores the reliability and full compliance of its quality system with global regulatory standards. Dr. Chris Chen, CEO of WuXi Biologics, commented, "Our world-class quality system is the cornerstone to maintain the company's strong sustainable growth and has laid a solid foundation for our global network to support our clients worldwide. WuXi Biologics will continue to enable global partners in delivering life-saving treatments with speed and efficacy, ultimately benefiting patients worldwide." About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2024, WuXi Biologics is supporting 817 integrated client projects, including 21 in commercial manufacturing (excluding COVID CMO projects). WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON, Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing?, shedding light on the pharmaceutical industry's evolution in the region. The report explores critical challenges and opportunities, emphasizing the importance of strategic partnerships, local API production, and regulatory modernization to drive sustainable growth. Latin America's pharmaceutical market, valued at $98 billion, is projected to grow by 10.1% between 2021 and 20251. Discussions at the 2023 Summit LATAM in Barcelona and the 2024 Summit LATAM at CPhI Milan underscored the need for collaboration among industry stakeholders, government agencies, and academia to strengthen regional innovation and competitiveness. With increasing global demand for pharmaceuticals, Latin America has the potential to become a key player in the industry by leveraging its manufacturing capabilities and investing in research and development. Addressing regulatory challenges and fostering a robust innovation ecosystem will be essential in ensuring long-term success and sustainability for the region. Henry Levy, President, Life Sciences and Healthcare, Clarivate, said: "The Latin American pharmaceutical sector is at a pivotal moment. By fostering collaboration across key stakeholders—including regulators, manufacturers, and researchers—we can unlock new opportunities for growth and development in the region. Strengthening the local pharmaceutical ecosystem through strategic partnerships and data-driven insights will not only enhance supply chain resilience but also ensure that life-changing therapies reach patients more efficiently. At Clarivate, we are committed to providing the necessary intelligence to support this transformation." The Brazilian Pharmaceutical Industry Association (ABIQUIFI), a non-profit organization uniting pharmaceutical companies to advance the development and production of pharmaceutical ingredients in Brazil, plays a pivotal role as a key partner in these discussions. Norberto Prestes, CEO, ABIQUIFI, stated, "The industry's evolution in Latin America depends on fostering transparency and trust in partnerships. By investing in local API production and strengthening regional supply chains, we can reduce dependency on external markets and drive economic growth. Moreover, innovation and regulatory modernization are crucial to positioning Latin America as a competitive player in the global pharmaceutical industry. These efforts will require sustained collaboration between the public and private sectors, and we look forward to continuing to lead these critical discussions. We'll continue working closely with Clarivate to drive innovation, leveraging valuable data to build the right path for sustainable growth and advancement." The report highlights key findings from recent discussions, including: The need for greater transparency and collaboration in strategic partnerships The potential of local API production to reduce reliance on imports and enhance supply chain security The role of artificial intelligence in modernizing regulatory processes and improving efficiency The importance of consistent, long-term policies to encourage investment and innovation Clarivate remains committed to supporting the region's life sciences and healthcare sectors by providing reliable, data-driven insights. By fostering industry-wide dialogue and collaboration, the company aims to contribute to an ecosystem of sustainable innovation in Latin America. To access the full Clarivate report, How is Latin America Growing?, visit here. To learn more about how Clarivate can help healthcare companies inform and shape the drug discovery, development and delivery process, visit here. About Clarivate Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com Media Contact:Catherine DanielDirector External Communications, Life Sciences & Healthcare, Clarivatenewsroom@clarivate.com 1 Source: InFigures: Latin America 2022. Pharma Boardroom. https://pharmaboardroom.com/country-reports/infigures-latin-america-2022/
KUALA LUMPUR, Malaysia, Feb. 27, 2025 /PRNewswire/ -- Malaysia is facing a growing environmental and public health threat due to improper disposal of pharmaceutical waste. Research indicates that 67% of Malaysians discard expired medications incorrectly—either by flushing them down the toilet or tossing them in regular trash—leading to contamination of the country's vital water sources. With 99% of Malaysia's domestic water supply coming from surface water, the presence of pharmaceutical residues in rivers and lakes poses serious risks to both human health and ecosystems. (From left: Mindy Leong (Branding Manager of Alpro Pharmacy); Ostwin Paw ( CEO of Alpro Foundation); Professor Dato. Dr. Yamin bin Yassin (Rector of UiTM Negeri Sembilan); Prof. Dato Dr. Abu Bakar Abdul Majeed (Dean of the Faculty of Pharmacy in UiTM) ) A study by the Malaysian Ministry of Health found that only 15% of the population is aware of the correct methods for medication disposal. Meanwhile, researchers have detected traces of antibiotics, hormones, and painkillers in 35% of Malaysia's waterways, threatening aquatic life and increasing antibiotic resistance risks. One of the biggest challenges remains accessibility—over 60% of rural households lack nearby pharmaceutical waste disposal facilities. Recognizing the urgency of the issue, Alpro Foundation, the corporate social responsibility (CSR) arm of Alpro Pharmacy, Malaysia's largest prescription pharmacy chain, is taking a monumental step toward environmental sustainability and public health by signing a Memorandum of Agreement (MoA) with Universiti Teknologi MARA (UiTM). A Strategic Collaboration to Drive Change The MoA encompasses four key initiatives designed to advance pharmaceutical waste management and public awareness: Identifying, Categorizing, and Cost Estimation of Public Pharmaceutical Waste – Research will be conducted to classify and quantify pharmaceutical waste, assessing its environmental impact and economic implications. Readiness Assessment of Stakeholders – This study will evaluate the preparedness of key stakeholders, including healthcare providers and the public, in implementing safe medication disposal practices across Malaysia. Development of Educational Tools – UiTM and Alpro Pharmacy will create innovative educational materials designed for both pharmacy students and the general public to promote best practices in medication disposal. Community-Based Awareness Campaigns – A grassroots approach will be employed to engage communities and drive behavioral change regarding pharmaceutical waste disposal. A Nation-Wide Effort for a Sustainable Future Since the launch of the Safe Medication Disposal Campaign in 2021, Alpro Foundation has made significant strides: Partnered with over 800 schools and universities, reaching more than 300,000 students through school talks. Collected more than 100,000 pledges nationwide from walk-in customers, committing to the safe disposal of unwanted medications. Installed safe medication disposal bins in all 300 Alpro Pharmacy outlets nationwide, ensuring convenient and responsible disposal access for the public. Reached over 50,000 families through safe medication disposal outreach programs, coloring competitions, medication safety competitions, and public education events. In 2025, the Foundation aims to further expand its impact with the Faculty of Pharmacy, UiTM: Enhancing Public Pharmaceutical Waste Identification & Management: Conducting large-scale data collection and classification of pharmaceutical waste to better understand its impact and advocate for improved disposal methods. Educating Stakeholders on Readiness & Implementation: Engaging with over 350,000 individuals, including students and corporate stakeholders, to assess and enhance their preparedness for responsible pharmaceutical waste disposal. Developing Educational Tools for Public & Pharmacy Students: Expanding outreach programs to 250,000 families through school talks, interactive workshops, and community engagement activities to improve public understanding of proper disposal techniques. Strengthening Community-Based Awareness Campaigns: Establishing a dedicated awareness landmark, the "Little Red House", outside Alpro's headquarters, serving as both a disposal hub and an educational center for the public. Protecting Malaysia's Water Sources Through Responsible Disposal "We have seen a growing number of healthcare providers and individuals recognizing the importance of safe medication disposal, but more needs to be done," said Mr. Ostwin Paw, CEO of Alpro Foundation. "This MoA with UiTM represents a crucial step forward in protecting our environment, enhancing public education, and ensuring future generations inherit a healthier planet." Professor Amrahi Buang, President of the Malaysian Pharmacists Society, added, "Proper pharmaceutical waste management is no longer optional—it is a necessity. This partnership between Alpro Pharmacy and UiTM will help shape the future of safe medication disposal practices in Malaysia." En. Shahiri, Senior Principal Assistant Director of Program Perkhidmatan Farmasi, Ministry of Health, who is also leading My MediSafe initiative remarked, "The Ministry of Health strongly supports this initiative, as improper medication disposal poses risks to both public health and the environment. We look forward to working with all stakeholders to enhance awareness and facilitate responsible disposal solutions." Prof. Dato Dr Yamin Bin Yassin, Rector of UiTM Cawangan Negeri Sembilan, stated, "This collaboration with Alpro Pharmacy aligns with UiTM's commitment to community engagement and sustainability. By combining research, education, and public awareness, we can drive meaningful change in pharmaceutical waste management." Alpro Foundation invites everyone to take part in this vital initiative. Dispose of your unwanted medications responsibly and contribute to a cleaner, safer Malaysia. For more details on the Alpro Safe Medication Disposal Campaign and to find a disposal bin near you, please visit https://www.alpropharmacy.com/services/medication-disposal-service/ About Alpro Pharmacy With a humble beginning starting with a single pharmacy outlet in the small town of Port Dickson in 2002, Alpro Pharmacy is now a diversified community chain pharmacy that provides comprehensive primary healthcare solutions via over 300 outlets including Alpro Pharmacy, Alpro Clinic, Alpro Physio and Alpro Baby, both online and offline, nationwide. It is supported by a team of more than 650 healthcare professionals, ranging from doctors, pharmacists, nutritionists, dietitians to physiotherapists and many other healthcare professionals. Serving more than 3 million families in Malaysia, Alpro Pharmacy is the first and only community pharmacy in the country to provide RM1 million product liability insurance to safeguard the supply of genuine medications. With over 500,000 prescriptions filled per year, Alpro Pharmacy is also the largest prescription pharmacy chain in Malaysia. For more information, please visit https://www.alpropharmacy.com.
SEOUL, South Korea and NEWPORT BEACH, Calif., Feb. 27, 2025 /PRNewswire/ -- Medit (www.medit.com), a global leader in digital dentistry, is set to revolutionize the digital All-on-X workflow, making it more accessible, efficient, and intuitive for Medit scanner users. Medit SmartX Starting in March, Medit will introduce the Medit All-on-X Workflow, Medit SmartX, enabling users to effortlessly scan to verify implant positions and initiate the workflow without the need for complex procedures or additional scanner purchases. With the flexibility to work with scanbodies of their choice, users can seamlessly integrate the workflow into their existing setup without being restricted to specific components. A Preview of Medit SmartX Advantages 1. Designed for All UsersClear, easy-to-follow protocol ensure a seamless adoption process for both new and experienced users. 2. Streamlined WorkflowEnhance efficiency with real-time automatic library alignment, providing an intuitive process and simplifying the scanning workflow. 3. Optimized Scanning DataRedefining scan alignment and capture techniques to deliver exceptionally precise and detailed scan results. 4. No Additional ScannerMedit scanner users can instantly initiate the workflow using their existing Medit scanner models (available for Medit i900, Medit i700 Wireless, Medit i700, and Medit i600). Medit disrupted the market in 2018 with its first intraoral scanner, offering dentists a high-precision, user-friendly option at a significantly lower cost than competitors. Building on this success, Medit introduced the best-selling i700 in 2021, followed by the i700 Wireless and i600 in 2022, and the i900 in 2024, providing a comprehensive range of scanners for all types of dental practices. With innovative solutions never before seen in the market, Medit continues to redefine the standards of digital dentistry. Stay tuned for the official launch of the Medit SmartX on March 18th. About Medit MEDIT is a global provider of 3D intraoral scanners and an all-in-one digital dentistry platform, based on its own patented state-of-the-art technology. The company also develops innovative software for digital dentistry, supporting collaborative workflows between dental clinics and labs. MEDIT has been headquartered in Seoul, South Korea since its inception in 2000. The company also has representatives located in the Americas and Europe and boasts a global network of distributors in over 100 countries. For detailed information about MEDIT products and software, please visit MEDIT official website(www.medit.com). For other various content, please refer to MEDIT official YouTube(youtube.com/user/meditcompany) and other social media channels (instagram.com/meditcompany/).
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy and safety of JSKN003 versus trastuzumab emtansine (T-DM1) for the treatment of HER2-positive advanced breast cancer. Breast cancer is one of the most common malignant tumors among women worldwide and the most prevalent cancer in women in China. HER2-positive breast cancer is the most aggressive and highly malignant subtype. In recent years, the diagnosis and treatment of HER2-positive breast cancer has significantly improved. However, recurrent and metastatic breast cancer still has significant unmet clinical needs. JSKN003 is an anti-HER2 biparatopic ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. The Phase III clinical studies of JSKN003 for HER2 low-expressing breast cancer (JSKN003-302) and platinum-resistant ovarian cancer (JSKN003-306) are currently progressing smoothly. JSKN003-301 is a randomized, controlled, open-label, multicenter, Phase III clinical study aimed at evaluating the efficacy and safety of JSKN003 compared to emtansine (T-DM1) in the treatment of patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who have previously received trastuzumab or taxane-based therapies. The primary endpoint of the study is progression-free survival (PFS) as assessed by the Blinded Independent Review Committee (BIRC). The expedited progression of this study is anticipated to offer a treatment option with improved efficacy and safety for this patient population, further improving prognosis and quality of life. About JSKN003 JSKN003 is an anti-HER2 biparatopic antibody-drug conjugate (ADC), which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. JSKN003 can bind HER2 on the surface of tumor cells and release topoisomerase I inhibitors (TOPIi) through cellular endocytosis, thereby exert anti-tumor effects. Compared with its ADC counterparts, JSKN003 demonstrated better serum stability and stronger bystander effect, which effectively expands the therapeutic window. Multiple clinical studies at various stages of JSKN003 are currently being conducted in China and Australia. Clinical research results have demonstrated favorable tolerability and safety profile, with promising efficacy of JSKN003 in heavily pretreated patients with advanced solid tumors, especially in patients with HER2-expressing breast cancer, platinum-resistant ovarian cancer (PROC), or high HER2-expressing solid tumors. In September 2024, the Company entered a licensing agreement with JMT-Bio Technology Co., Ltd. ("JMT-Bio"), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK), pursuant to which, JMT-Bio was granted the exclusive license and sublicense rights to develop, sell, offer for sale and commercialize JSKN003, for the treatment of tumor-related indications (the "Field") in mainland China (excluding Hong Kong, Macau or Taiwan) (the "Territory") and become the sole marketing authorization holder for JSKN003 for the Field in the Territory. Alphamab retains the sole right to supply JSKN003. About Alphamab Oncology Alphamab Oncology is a leading biopharmaceutical company committed to the development, manufacturing, and commercialization of cutting-edge biotherapeutics for the treatment of cancer. On December 12, 2019, the company was successfully listed on the Main Board of the Hong Kong Stock Exchange, trading under the stock code 9966. Our integrated platform seamlessly combines research, development, and manufacturing capabilities for biologics. We take pride in our extensive intellectual property portfolio, which encompasses protein/antibody engineering, antibody screening, and multi-module/multi-functional antibody modification. Distinguished by a globally competitive pipeline, Alphamab Oncology specializes in antibody-drug conjugation (ADC), single domain antibody, and bispecific antibodies. Notably, Envafolimab, the world's first subcutaneously injectable PD-L1 inhibitor, was approved by Chinese authorities in 2021, making a significant breakthrough in the convenience and accessibility of cancer treatment. Three assets are currently undergoing Phase III or pivotal clinical trials, and several other bispecific ADC new drug candidates are in early clinical stage. Multiple strategic collaborations based on innovative products or technology platforms have been established with partners such as CSPC, Arrivent, and Glenmark. Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is dedicated to the development of safe, effective and affordable drugs, leveraging a global competitive edge.
Medical/Pharmaceuticals
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
